Dimethyl fumarate attenuates lipopolysaccharide-induced mitochondrial injury by activating Nrf2 pathway in cardiomyocytes

Life Sci. 2019 Oct 15:235:116863. doi: 10.1016/j.lfs.2019.116863. Epub 2019 Sep 9.

Abstract

Aims: To determine whether dimethyl fumarate (DMF) can protect against lipopolysaccharide (LPS) -induced myocardial injury.

Main methods: H9c2 cells pretreated with or without DMF were stimulated with LPS. Cell viability and apoptosis were evaluated. Nrf2 and HO-1 expression were detected using Western blotting. Mitochondrial morphology, mitochondrial superoxide production were observed using confocal microscope. Mitochondrial respiration function was measured using Seahorse bioanalyzer.

Key findings: (1) The cell viability decreased, LDH release and apoptosis increased in LPS- challenged H9c2 cells. DMF pretreatment brought a higher cell viability, and a lower LDH leakage and apoptosis than those of LPS group (P < 0.01). (2) DMF pretreatment resulted in an increased Nrf2 and HO-1 expression, and enhanced nuclear Nrf2 level in LPS-challenged cells (P < 0.01). (3) Nrf2-siRNA could inhibit DMF-induced enhancement of HO-1 expression and cell viability, and partly abolish DMF-induced reduction of LDH leakage and apoptosis. (4) ERK1/2 inhibitor PD98059 could not only prevent the DMF-induced enhancement of nuclear Nrf2 and HO-1, but also inhibit DMF-induced increase in cell viability. (5) Compared with LPS-challenged cells, DMF pretreatment caused a lower production of mitochondrial superoxide and a higher mitochondrial membrane potential, which could be abolished by Nrf2-siRNA. (6) DMF could attenuate LPS-induced mitochondrial fragmentation and improve mitochondrial respiration function by enhancement of the oxygen consumption rate of basal respiration and ATP production in LPS-challenged cells (P < 0.01).

Significance: DMF protects cardiomyocytes against LPS-induced damage. ERK1/2-dependent activation of Nrf2/HO-1 pathway is responsible for DMF-induced cardioprotection via reduction of oxidative stress, improvement of mitochondrial morphology and energy metabolism.

Keywords: Dimethyl fumarate; Lipopolysaccharide; Mitochondria; Nrf2.

MeSH terms

  • Adenosine Triphosphate / biosynthesis
  • Apoptosis / drug effects
  • Cell Survival / drug effects
  • Cells, Cultured
  • Dimethyl Fumarate / antagonists & inhibitors
  • Dimethyl Fumarate / pharmacology*
  • Flavonoids / pharmacology
  • Heme Oxygenase-1 / metabolism
  • Humans
  • L-Lactate Dehydrogenase / metabolism
  • Lipopolysaccharides / adverse effects
  • Membrane Potential, Mitochondrial / drug effects
  • Mitochondria / drug effects*
  • Mitochondria / metabolism
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • NF-E2-Related Factor 2 / antagonists & inhibitors
  • NF-E2-Related Factor 2 / metabolism*
  • Oxygen Consumption / drug effects
  • Protective Agents / pharmacology
  • RNA, Small Interfering / pharmacology
  • Signal Transduction / drug effects*
  • Superoxides / metabolism

Substances

  • Flavonoids
  • Lipopolysaccharides
  • NF-E2-Related Factor 2
  • NFE2L2 protein, human
  • Protective Agents
  • RNA, Small Interfering
  • Superoxides
  • Adenosine Triphosphate
  • L-Lactate Dehydrogenase
  • HMOX1 protein, human
  • Heme Oxygenase-1
  • Dimethyl Fumarate
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one